Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives

References

• Global, regional, and national burden of neurological disorders. 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459–480.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018 Feb 21;19(1):17.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Becker WJ, Findlay T, Moga C, et al. Guideline for primary care management of headache in adults. Can Fam Physician. 2015 Aug;61(8):670–679.
   PubMed Web of Science ®Google Scholar
• Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018 Feb;17(2):174–182.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European headache federation and lifting the burden: the global campaign against headache. J Headache Pain. 2019 May 21;20(1):57.
   PubMed Web of Science ®Google Scholar
• Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018 Apr;15(2):274–290.
   PubMed Web of Science ®Google Scholar
• Borkum JM. CGRP and brain functioning: cautions for migraine treatment. Headache. 2019 Sep;59(8):1339–1357.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982 Jul 15;298(5871):240–244.
   PubMed Web of Science ®Google Scholar
• Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988 Apr;25(1):195–205.
   PubMed Web of Science ®Google Scholar
• Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature. 1983 Jul 14-20;304(5922):129–135.
   PubMed Web of Science ®Google Scholar
• Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985 Nov 20;62(1):131–136.
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 Mar 11;350(11):1104–1110.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Joint EL. 1994 Wolff award presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 1994 Jul-Aug;34(7):394–399.
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Israel H, Neeb L, et al. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother. 2017 Sep;18(13):1409–1415.
   PubMed Web of Science ®Google Scholar
• Amrutkar DV, Ploug KB, Hay-Schmidt A, et al. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain. 2012 Apr;153(4):830–838.
   PubMed Web of Science ®Google Scholar
• Labastida-Ramirez A, Rubio-Beltran E, Haanes KA, et al. Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain. 2020 May;161(5):1092–1099.
   PubMed Web of Science ®Google Scholar
• Kilinc E, Guerrero-Toro C, Zakharov A, et al. Serotonergic mechanisms of trigeminal meningeal nociception: implications for migraine pain. Neuropharmacology. 2017;116:160–173.
   PubMed Web of Science ®Google Scholar
• Villalon CM, VanDenBrink AM. The role of 5-hydroxytryptamine in the pathophysiology of migraine and its relevance to the design of novel treatments. Mini Rev Med Chem. 2017;17(11):928–938.
   PubMed Web of Science ®Google Scholar
• Ho TW, Edvinsson L, Goadsby PJCGRP. and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010 Oct;6(10):573–582.
   PubMed Web of Science ®Google Scholar
• Tajti J, Uddman R, Moller S, et al. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J Auton Nerv Syst. 1999 May 28;76(2–3):176–183.
   PubMedGoogle Scholar
• Eftekhari S, Warfvinge K, Blixt FW, et al. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013 Nov;14(11):1289–1303.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010 Aug 25;169(2):683–696.
   PubMed Web of Science ®Google Scholar
• Haanes KA, Edvinsson L. Pathophysiological mechanisms in migraine and the identification of new therapeutic targets. CNS Drugs. 2019 Jun;33(6):525–537.
   PubMed Web of Science ®Google Scholar
• Cottrell GS. CGRP receptor signalling pathways. Handb Exp Pharmacol. 2019;255:37–64.
   PubMedGoogle Scholar
• Messlinger K. The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain. 2018 Mar 12;19(1):22.
   PubMedGoogle Scholar
• Simonetti M, Giniatullin R, Fabbretti E. Mechanisms mediating the enhanced gene transcription of P2X3 receptor by calcitonin gene-related peptide in trigeminal sensory neurons. J Biol Chem. 2008 Jul 4;283(27):18743–18752.
   PubMed Web of Science ®Google Scholar
• Fabbretti E, D’Arco M, Fabbro A, et al. Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide. J Neurosci. 2006 Jun 7;26(23):6163–6171.
   PubMed Web of Science ®Google Scholar
• Edvinsson JCA, Warfvinge K, Krause DN, et al. C-fibers may modulate adjacent Adelta-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain. 2019 Nov 12;20(1):105.
   PubMed Web of Science ®Google Scholar
• Quartu M, Serra MP, Boi M, et al. TRPV1 receptor in the human trigeminal ganglion and spinal nucleus: immunohistochemical localization and comparison with the neuropeptides CGRP and SP. J Anat. 2016 Dec;229(6):755–767.
   PubMed Web of Science ®Google Scholar
• Gupta S, Mehrotra S, Avezaat CJ, et al. Characterisation of CGRP receptors in the human isolated middle meningeal artery. Life Sci. 2006 Jun 13;79(3):265–271.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Fredholm BB, Hamel E, et al. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985 Jul 31;58(2):213–217.
   PubMed Web of Science ®Google Scholar
• Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia. 1997 May;17(3):166–174.
   PubMed Web of Science ®Google Scholar
• Capuano A, De Corato A, Lisi L, et al. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain. 2009 Aug;6(5):43.
   Google Scholar
• Goadsby PJ, Holland PR. An update: pathophysiology of migraine. Neurol Clin. 2019 Nov;37(4):651–671.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015 Aug;80(2):193–199.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017 Apr;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• BS RAY, HG WOLFF. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg. 1940;41(4):813–856.
   Google Scholar
• Levy D, Labastida-Ramirez A, MaassenVanDenBrink A. Current understanding of meningeal and cerebral vascular function underlying migraine headache. Cephalalgia. 2019 Nov;39(13):1606–1622.
   PubMed Web of Science ®Google Scholar
• Kilinc E, Dagistan Y, Kukner A, et al. Salmon calcitonin ameliorates migraine pain through modulation of CGRP release and dural mast cell degranulation in rats. Clin Exp Pharmacol Physiol. 2018 Jun;45(6):536–546.
   PubMed Web of Science ®Google Scholar
• Kilinc E, Tore F, Dagistan Y, et al. Thymoquinone inhibits neurogenic inflammation underlying migraine through modulation of calcitonin gene-related peptide release and stabilization of meningeal mast cells in glyceryltrinitrate-induced migraine model in Rats. Inflammation. 2020 Feb;43(1):264–273.
   PubMed Web of Science ®Google Scholar
• Meningeal DL Neurogenic Inflammation and dural mast cells in migraine pain.
   Google Scholar
• Koyuncu Irmak D, Kilinc E, Tore F. Shared fate of meningeal mast cells and sensory neurons in migraine. Front Cell Neurosci. 2019;13:136.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019 Aug;15(8):483–490.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Joutsa J, Cohen AL, et al. Mapping migraine to a common brain network. Brain. 2020 Feb 1;143(2):541–553.
   PubMedGoogle Scholar
• Barbanti P, Fofi L, Aurilia C, et al. Does the migraine attack start in the cortex and is the cortex critical in the migraine process? Neurol Sci. 2019 May;40(Suppl 1):31–37.
   PubMedGoogle Scholar
• Sutherland HG, Griffiths LR. Genetics of migraine: insights into the molecular basis of migraine disorders. Headache. 2017 Apr;57(4):537–569.
   PubMed Web of Science ®Google Scholar
• Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Adelta) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017 Nov 1;37(44):10587–10596.
   PubMed Web of Science ®Google Scholar
• Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019 Apr 17;20(1):37.
   PubMedGoogle Scholar
• Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019 Jun;28(6):555–567.
   PubMed Web of Science ®Google Scholar
• Gingell JJ, Hendrikse ER, Hay DL. New insights into the regulation of CGRP-family receptors. Trends Pharmacol Sci. 2019 Jan;40(1):71–83.
   PubMed Web of Science ®Google Scholar
• Yarwood RE, Imlach WL, Lieu T, et al. Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12309–12314.
   PubMed Web of Science ®Google Scholar
• Agency EM Aimovig, INN-erenumab. [cited 2020 May 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/aimovig-epar-product-information_it.pdf
   Google Scholar
• Agency EM. Ajovy, INN-fremanezumab [Feb 25, 2020]. [cited 2020 May 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/ajovy-epar-product-information_it.pdf
   Google Scholar
• Ornello R, Tiseo C, Frattale I, et al. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain. 2019 Oct 30;20(1):99.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y. et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med. 2017;11;377(22):2123–2132.
   Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018 May;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018 September;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019 Sept;394(10203):1030–1040.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME. et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;11;377(22):2113–2122.
   Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018 Dec;91(24):e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019 Mar;39(3):445–458.
   PubMed Web of Science ®Google Scholar
• Tiseo C, Ornello R, Pistoia F, et al. How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. J Headache Pain. 2019 May;20(1):49.
   PubMed Web of Science ®Google Scholar
• Israel H, Neeb L, Reuter U. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. Curr Pain Headache Rep. 2018 Apr;22(5):38.
   PubMed Web of Science ®Google Scholar
• Martelletti P. Erenumab is effective in reducing migraine frequency and improving physical functioning. BMJ Evid Based Med. 2019 Apr;24(2):76.
   PubMedGoogle Scholar
• Lionetto L, Cipolla F, Guglielmetti M, et al. Fremanezumab for the prevention of chronic and episodic migraine. Drugs Today (Barc). 2019 Apr;55(4):265–276.
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019 Oct;39(11):1455–1464.
   PubMed Web of Science ®Google Scholar
• Ashina M, Kudrow D, Reuter U, et al. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019 Dec;39(14):1798–1808.
   PubMed Web of Science ®Google Scholar
• Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology. 2020 Feb 4;94(5):e497–e510.
   PubMed Web of Science ®Google Scholar
• Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018 Nov;18(1):188.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019 May 14;92(20):e2309–e2320.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018 Nov 24;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur J Neurol. 2019 Apr;;27(4):609-618..
   Web of Science ®Google Scholar
• Ruff DD, Ford JH, Tockhorn-Heidenreich A, et al. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. Cephalalgia. 2019 Jul;39(8):931–944.
   PubMed Web of Science ®Google Scholar
• Mulleners W, Kimb B, Láinez MJ, et al. A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: results from the 3-month double-blind treatment phase of the conquer study. J Neurol Sci. 2019;405S(2019):105478.
   Web of Science ®Google Scholar
• Rubio-Beltran E, Labastida-Ramirez A, Haanes KA, et al. Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. Cephalalgia. 2019 Dec;39(14):1735–1744.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Hernandez A, Marichal-Cancino BA, MaassenVanDenBrink A, et al. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):25–41.
   PubMed Web of Science ®Google Scholar
• Li CC, Dockendorf M, Kowalski K, et al. Population PK analyses of ubrogepant (MK-1602), a CGRP receptor antagonist: enriching in-clinic plasma PK sampling with outpatient dried blood spot sampling. J Clin Pharmacol. 2018 Mar;58(3):294–303.
   PubMed Web of Science ®Google Scholar
• Curto M, Capi M, Cipolla F, et al. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother. 2020;3:1–5.
   Google Scholar
• Tong G, Savant I, Jariwala N, et al. Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects. J Headache Pain. 2013;14:118.
   Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014 Feb;34(2):114–125.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019 Jul 11;381(2):142–149.
   PubMed Web of Science ®Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737–745.
   PubMed Web of Science ®Google Scholar
• Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016 Aug;36(9):887–898.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019 Dec 5;381(23):2230–2241.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. Jama. 2019 Nov 19;322(19):1887–1898.
   PubMed Web of Science ®Google Scholar
• Lipton R, Ailani J, Hutchinson S, et al. Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b/3 study [Abstract]. Cephalalgia. 2019;39:182–183.
   Web of Science ®Google Scholar
• Dodick D, Ailani J, Goadsby PJ, et al. Responder rates to atogepant in patients with episodic migraine: a post Hoc analysis of results from a phase 2b/3, randomized, double-blind, placebo-controlled trial [Abstract]. Cephalalgia. 2019;39(1_Suppl):183–184.
   Google Scholar
• Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010 Sep 1;334(3):746–752.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltran E, Chan KY, Danser AJ, et al. Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries. Cephalalgia. 2019;1:333102419884943.
   Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019 Jan;20(1):6.
   PubMed Web of Science ®Google Scholar
• Ornello R, Frattale I, Pistoia F, et al. Erenumab plus subcutaneous immunoglobulin in a patient with comorbid chronic migraine and myasthenia gravis. Headache. 2020 Feb;60(4):787-788.
   Web of Science ®Google Scholar
• Ailani J, Lipton RB, Hutchinson S, et al. Long-term safety evaluation of ubrogepant for the acute treatment of migraine: phase 3, randomized, 52-week extension trial. Headache. 2020 Jan;60(1):141–152.
   PubMed Web of Science ®Google Scholar
• Costa C, Tozzi A, Rainero I, et al. Cortical spreading depression as a target for anti-migraine agents. J Headache Pain. 2013 Jul;23(14):62.
   Google Scholar
• Tozzi A, de Iure A, Di Filippo M, et al. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18985–18990.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. Correction to: european headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019 May 23;20(1):58.
   PubMedGoogle Scholar
• Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020 Apr 7;21(1):32.
   PubMed Web of Science ®Google Scholar
• Sussman M, Benner J, Neumann P, et al. Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia. 2018 Sep;38(10):1644–1657.
   PubMed Web of Science ®Google Scholar
• Pomes LM, Guglielmetti M, Bertamino E, et al. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019 May 17;20(1):56.
   PubMedGoogle Scholar
• Martelletti P, Edvinsson L, Ashina M. Shaping the future of migraine targeting Calcitonin-Gene-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). J Headache Pain. 2019 May 23;20(1):60.
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Rev Neurother. 2019 Aug;19(8):769–776.
   PubMed Web of Science ®Google Scholar
• American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019 Jan;59(1);1–18.
   PubMed Web of Science ®Google Scholar
• Sacco S, Braschinsky M, Ducros A, et al. European Headache Federation consensus on the definition of resistant and refractory migraine. J Headache Pain. 2020;21(1).
   Web of Science ®Google Scholar
• Torres-Ferrus M, Quintana M, Fernandez-Morales J, et al. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017 Feb;37(2):104–113.
   PubMed Web of Science ®Google Scholar
• Ford JH, Jackson J, Milligan G, et al. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017 Nov;57(10):1532–1544.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008 Sep;48(8):1157–1168.
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Buse DC, Manack AN, et al. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012 Feb;16(1):86–92.
   PubMed Web of Science ®Google Scholar
• de Vries T, MaassenVanDenBrink A. CGRP-targeted antibodies in difficult-to-treat migraine. Nat Rev Neurol. 2019 Dec;15(12):688–689.
   PubMed Web of Science ®Google Scholar
• Ziegeler C, May A. Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class. Headache. 2020 Feb;60(2):469–470.
   PubMed Web of Science ®Google Scholar
• Do TP, Guo S, Ashina M. Correction to: therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019 May 17;20(1):55.
   PubMedGoogle Scholar
• Tfelt-Hansen P, Loder E. The emperor’s new gepants: are the effects of the new oral CGRP antagonists clinically meaningful? Headache. 2019 Jan;59(1):113–117.
   PubMed Web of Science ®Google Scholar
• Mullin K, Kudrow D, Croop R, et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020 May 19;94(20):e2121-e2125.
   PubMed Web of Science ®Google Scholar
• Gingell JJ, Rees TA, Hendrikse ER, et al. Distinct patterns of internalization of different calcitonin gene-related peptide receptors. ACS Pharmacol Transl Sci. 2020 Feb 26;3(2):296-304.
   Google Scholar